Marc Richards, MD is a nephrologist at Florida Kidney Physicians, LLC and Director of the FKP Glomerulonephritis Center of Excellence in Boca Raton, Florida.

centered largely on controlling blood pressure, managing diabetes, and using renin-angiotensin system blockade when appropriate. Today, that approach has expanded considerably, with a growing number of disease-modifying therapies targeting distinct pathways involved in kidney injury and progression.

CKD affects more than 1 in 7 US adults, yet many patients remain unaware they have the disease, underscoring the need for earlier recognition and more effective treatment strategies.

The emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and other therapies has transformed the clinical approach to slowing CKD progression.

, Marc Richards, MD, a nephrologist at Florida Kidney Physicians, discusses how this expanding evidence base is changing CKD management, the role of combination therapy, and why clinicians should continue adopting new treatment strategies.

Q&A: Expanding Era of Evidence-Based CKD Care, With Marc Richards, MD

When you're thinking about managing chronic kidney disease in 2026, what do you consider the essential components of evidence-based care?

Richards: I think what's amazing is that we actually have evidence-based care now. Up until a few years ago, it was, you know, maybe take care of your blood pressure, take care of your blood sugar, maybe take an ACE inhibitor, and avoid medicines that are bad for the kidneys. And really, outside of that, there was nothing we could really tell patients.

But now our data is exploding. We have evidence with ACE inhibitors and ARBs for proteinuric kidney disease states. We have SGLT2 inhibitors becoming a standard of care. We now have the nonsteroidal MRAs that are on the market, both in diabetic and—now we're learning—non-diabetic kidney disease, that could benefit our patients. Data is emerging with GLP‑1 agonists.

Also, nephrology is teeming with these new clinical trials that can help us really get more medicines to the forefront and have a really good evidence base to manage our patients.

As you’ve mentioned, there are so many new therapies that have emerged in recent years that target very different pathways. How has that shifted your thinking about combination therapy or selecting treatments for individual patients?

Richards: We like that there was the CONFIDENCE trial, which was really recent, where they looked at combining SGLT2 inhibitors with finerenone, which is the nonsteroidal mineralocorticoid receptor antagonist. They showed that you got pretty good reduction in proteinuria with either of those agents, but when you use them together, you actually had a synergistic effect and the protein in the urine got even better.

I think sometimes patients might get a little frustrated when we're adding medicine on top of medicine, but if you explain that they all work together from different angles to protect kidneys, the patients are willing to accept combination therapy.

I don't know if that answered your question totally about the individualized care, but certainly if a patient does have protein in the urine, that would make me more willing to be more aggressive with that type of therapy.

: If every nephrologist listening today could make one change in their practice tomorrow, what would you want it to be?

Richards: I really think it's being earlier adopters of this evidence. I think a lot of nephrologists have been sort of swayed to sleep by 20 to 25 years of really no groundbreaking developments in how we manage chronic kidney disease.

We've gone from that to now potentially three new classes of agents on the market, and potentially more, that can delay progression of kidney disease in our patients and prevent progression to end-stage kidney disease.

So I think we just need to wake up and realize that we have this great evidence out there. We have new classes of agents out there that are readily available to use on our patients, and we can really make a difference in the lives of our patients.

Was there anything else that I didn't ask about that you think you would want to highlight or add?

Richards: I think the only other thing would be that in addition to what we now have, we always have the potential for more. At least our practice, and a lot of academic and private practices throughout the country, are very active with clinical research.

Potentially the next great treatment is out there, but we just need to get patients into clinical trials to see if we can establish new standards of care to optimize management of our patients.

Editor’s Note: Richards reports no relevant disclosures.

National Institute of Diabetes and Digestive and Kidney Diseases. 

Kidney Disease Statistics for the United States

https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease

Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. 

. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816.

Articles

Chronic kidney disease care has shifted from largely supportive management—blood pressure and glycemic control, ACE inhibitor/ARB use in proteinuric disease, and avoidance of nephrotoxins—to a rapidly expanding, evidence-based, disease-modifying paradigm. With CKD affecting more than 1 in 7 US adults and substantial under-recognition, earlier detection and timely initiation of kidney-protective agents are increasingly critical. SGLT2 inhibitors have become foundational, nonsteroidal mineralocorticoid receptor antagonists are gaining broader applicability beyond diabetes, and GLP‑1 agonist data are emerging alongside robust trial activity.

Marc Richards, MD, discusses how new therapies and combination treatment strategies are transforming evidence-based care for chronic kidney disease.


Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Strategic Alliance Partnership

Expanding Era of Evidence-Based CKD Care, With Marc Richards, MD

Giovanni Leone, MD, from Israelite Hospital.

Oral GP-SOD for Vitiligo: Safety Profile, Dosing, and What's Next

 receiving oral gliadin-protected superoxide dismutase (GP-SOD) alongside targeted excimer phototherapy showed significantly greater improvement in both repigmentation and quality of life than those on phototherapy alone at 6 months.

The 6-month, single-center trial enrolled 40 patients with localized non-segmental vitiligo, randomly assigning half to add oral GP-SOD to excimer lamp treatment. Mean VASI improvement was -1.65 in the combination group versus -1.14 with phototherapy alone, a significant between-group difference (mean difference 0.51; 95% CI, 0.28-0.74; 

 Quality-of-life scores, measured with VitiQoL, also improved significantly more in the combination group, with a between-group difference of 5.59 (95% CI, 4.01-7.17;

, Giovanni Leone, MD, of the Photodermatology and Vitiligo Treatment Center at Israelite Hospital, discussed the safety findings behind those results, including why the combination group saw less treatment-related erythema, his recommended dosing protocol, and where he sees the research heading next.

Leone recommends 2 capsules of GP-SOD before breakfast and 2 before lunch, for a total of 4 capsules daily. He advised against evening dosing, noting that some patients reported insomnia when taking the supplement later in the day. Aside from that adjustment, he said tolerability has been consistently high.

Why Erythema Was Less Frequent With GP-SOD

Leone said GP-SOD itself produced no reported adverse events in the trial. The only adverse events were cases of erythema from the excimer lamp, a known effect of phototherapy.

He said the lower erythema rate in the combination group likely reflects a systemic photoprotective effect of antioxidants beyond their action on melanocyte-damaging mechanisms. Antioxidants are used clinically to build UV resistance even in patients without vitiligo, he said, which may explain the reduced erythema seen with GP-SOD.

Contraindications for GP-SOD and Phototherapy

Celiac disease or gluten hypersensitivity is an absolute contraindication to GP-SOD, Leone said, since the compound is gluten-based. Beyond that, he said exclusion criteria follow standard phototherapy contraindications: a family history of skin cancer or melanoma, UV-sensitive skin, and photodermatoses.

Next Steps: Polymorphic Light Eruption and New Protocols

Leone said his group is now exploring GP-SOD's photoprotective properties as a potential treatment or preventive strategy for polymorphic light eruption, a common sun-triggered photodermatosis. He said additional vitiligo protocol variations are also under consideration, though the current regimen remains his preferred approach for now.

“The most important message is that this treatment is…well tolerated, contributes to lower the risks of long-term phototherapy in terms of shortening the treatment period, [and] is very well accepted by the patients,” Leone said. “The rapidity of the treatment…make it a very good option. Without using very expensive and complicated drugs, we have a good result.”

Watch part 1 of our interview with Leone here: 

Oral GP-SOD Plus Targeted Phototherapy Boosts Vitiligo Repigmentation

Leone G, Bertold C, Vidolin AP, Fontas E, Passeron T. Combination of Oral Gliadin-Protected Superoxide Dismutase With Targeted Phototherapy in Vitiligo: A Prospective, Comparative, Randomized, Single-Blinded Study. 

Leone G. Oral GP-SOD Plus Targeted Phototherapy Boosts Vitiligo Repigmentation. HCPLive. Published on July 14, 2026. Accessed July 17, 2026. 

https://www.hcplive.com/view/oral-gp-sod-plus-targeted-phototherapy-vitiligo-repigmentation

Videos

Erythema was less frequent with combination therapy than with phototherapy alone, according to Giovanni Leone, MD.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Ann Marie Navar, MD, PhD, is an associate professor of cardiology at the University of Texas Southwestern Medical Center.

Enlicitide Receives FDA Approval for Hypercholesterolemia Following CORALreef Trials

 has officially approved the first-ever oral PCSK9 inhibitor, enlicitide, for the reduction of LDL-C in adult patients with 

Parent company Merck announced the approval on July 16, 2026, which followed positive data from the CORALreef Lipids and CORALreef HeFH trials. Enlicitide, approved under the name Lipfendra, substantially reduced LDL-C in both trials compared to placebo. The drug is administered in the form of 20 mg tablets as an adjunct to diet and exercise and has been approved for patients with heterozygous familial hypercholesterolemia (HeFH) in addition to hypercholesterolemia.

“This is really big,” Ann Marie Navar, MD, PhD, associate professor of medicine in the Division of Cardiology at UT Southwestern Medical Center, told 

 in an exclusive interview. “We now have an oral option that lowers LDL cholesterol by up to 60% on top of high-intensity statins and other background therapies. That’s huge in terms of getting more patients to goal.”

CORALreef Lipids was a multinational, double-blind, randomized, placebo-controlled trial including patients with a history of major 

atherosclerotic cardiovascular disease (ASCVD)

 events with an LDL-C level of ≥55 mg/dL or those who were at risk of a first ASCVD event with an LDL-C ≥70 mg/dL. These patients were assigned in a 2:1 ratio to receive either 20 mg enlicitide or placebo daily for 52 weeks.

The primary endpoint for CORALreef Lipids was mean percent change in LDL-C level from baseline to week 24. Secondary endpoints included mean percent LDL-C level changes at week 52 and mean percent change in non-HDL-C, apolipoprotein B (apoB), and lipoprotein(a) levels at week 24.

A total of 2909 patients were enrolled in CORALreef Lipids, of whom 1935 received enlicitide and 969 received placebo. Mean LDL-C level at baseline was 96.1 +/- 38.9 mg/dL, while mean percent change by week 24 was -57.1% (95% CI, -61.8 to -52.5) with enlicitide and 3% (95% CI, 0.9 to 5.1) with placebo. This represented an adjusted between-group difference of -55.8% (95% CI, -60.9 to -50.7; 

 <.001). The percent change in LDL-C at week 52, as well as the changes in Lp(a), non-HDL-C, and apoB at week 24, were all greater with enlicitide than placebo.

The CORALreef HeFH trial included patients ≥18 years old with HeFH who were actively using lipid-lowering therapy – either a moderate- or high-intensity statin – and who had an LDL-C level ≥55 mg/dL with a history of major ASCVD or an LDL-C level ≥70 mg/dL without a history of major ASCVD.

Participants were randomly assigned in a 2:1 ratio to receive either 20 mg of enlicitide or placebo once daily for 52 weeks. The primary outcome for CORALreef HeFH was the same as in CORALreef Lipids, while secondary endpoints included the same measurements of apoB and non-HDL-C, as well as percent change in LDL-C at week 52.

A total of 303 patients were enrolled and randomized, with 202 receiving enlicitide and 101 receiving placebo. Mean LDL-C at baseline was 119 mg/dL (standard deviation [SD], 41 mg/dL). Mean percentage change at week 24 in LDL-C was -58.2% in the enlicitide group versus 2.6% in the placebo group, with a between-group difference of -59.4% (95% CI, -65.6% to -53.2%; 

 <.001). The mean percentage change in LDL-C at week 52 was -55.3% in the enlicitide group versus 8.7% in the placebo group, with a between-group difference of -61.5% (95% CI, -69.4% to -53.7%; 

While the approval itself was based on the positive results from these 2 trials, Merck has also launched the ongoing CORALreef Outcomes study, which is examining the effects of enlicitide on cardiovascular morbidity and mortality over the long term.

“This approval is just the first step,” Navar said. “Now we actually have to get it into the hands of our clinician prescribers, and then ultimately into our patients. It’s going to come down to: are people going to use it, and are we going to be able to get payers and insurers to cover it for the patients that need it?”

Editors’ Note: Navar reports disclosures with Esperion Therapeutics, Bristol Myers Squibb, Amgen, Janssen Pharmaceuticals, Eli Lilly, Novo Nordisk, and others.

Merck. Merck’s LIPFENDRA (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the US FDA to Reduce LDL-C in Adults with Hypercholesterolemia. July 16, 2026. July 17, 2026. 

https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/

Navar AM, Mikhailova E, Catapano AL, et al. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. 

Ballantyne CM, Gellis L, Tardif J-C, et al. Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia. 

Ann Marie Navar, MD, PhD, discusses the groundbreaking approval of the first oral PCSK9 inhibitor and what it means for patients managing their LDL-C levels.

FDA News

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

 has accepted Camurus’ resubmitted new drug application (NDA) for CAM2029, an investigational once-monthly subcutaneous octreotide depot for patients with 

Announced on July 16, 2026, by parent company Camurus, the agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 18, 2026.

The filing follows a complete response letter (CRL) issued June 10, 2026, which cited observations from a current good manufacturing practice inspection of a third-party manufacturer. Camurus reported that no concerns involving clinical efficacy or safety were identified in the letter and said that the manufacturer completed remediation measures.

“We look forward to continuing the collaboration with the FDA to make CAM2029 available to patients with acromegaly in the United States,” Fredrik Tiberg, president and chief executive officer of Camurus, said in a statement.

Why FDA Previously Declined the CAM2029 Application

According to Camurus, the June CRL focused on manufacturing inspection observations rather than the clinical data package. The company said its contract manufacturer has completed corrective actions and confirmed readiness for inspection.

The NDA is supported by 7 clinical studies: 4 phase 1 studies, 1 phase 2 study, and 2 phase 3 studies from the ACROINNOVA program. CAM2029 is formulated using Camurus’ FluidCrystal drug-delivery technology and is designed for once-monthly self-administration with a prefilled autoinjector.

CAM2029 is already authorized for acromegaly in the European Union and the United Kingdom under the name Oczyesa. European product information describes it as a prolonged-release octreotide formulation administered subcutaneously every 4 weeks. Marketing applications are also under review in 2 additional countries, according to Camurus.

In the United States, long-acting octreotide is currently available as Sandostatin LAR Depot, an intramuscular formulation indicated for patients with acromegaly who have responded to and tolerated subcutaneous octreotide. Octreotide is a somatostatin analogue; its pharmacologic activity includes suppression of growth hormone secretion.

What the ACROINNOVA Phase 3 Program Reported

ACROINNOVA 1 was a randomized, double-blind, placebo-controlled phase 3 trial evaluating subcutaneous octreotide depot in acromegaly. Camurus characterized the trial as showing superior biochemical control over placebo. The company also reported improvements in symptoms, treatment satisfaction, and quality of life across the broader phase 3 program compared with baseline assessments during treatment with first-generation somatostatin receptor ligands, including octreotide and lanreotide. Additionally, Camurus described the safety profile as consistent with existing somatostatin receptor ligand therapy, with no new findings.

Acromegaly most often arises from a growth hormone–secreting pituitary tumor and produces elevated insulin-like growth factor 1 concentrations. Persistent biochemical activity is associated with progressive systemic complications, impaired quality of life, and excess mortality. Camurus cited an estimated prevalence of approximately 60 cases per million people.

The immediate regulatory question concerns whether the manufacturing deficiencies cited in June have been adequately resolved. No additional clinical studies were announced as part of the resubmission. The FDA decision expected in December will apply only to the proposed US indication and formulation.

Camurus’ NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA. PR Newswire. July 16, 2026. 

https://www.prnewswire.com/news-releases/camurus-nda-resubmission-for-cam2029-in-acromegaly-accepted-for-review-by-the-us-fda-302828303.html

Oczyesa: EPAR product information. European Medicines Agency. 

https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733797-1&h=3228323740&u=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fproduct-information%2Foczyesa-epar-product-information%5Fen.pdf&a=SmPC+Oczyesa%C2%AE

Sandostatin LAR Depot prescribing information. US Food and Drug Administration. 

https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733797-1&h=4289552022&u=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda%5Fdocs%2Flabel%2F2024%2F021008s049lbl.pdf&a=Prescribing+Information+SANDOSTATIN%C2%AE+LAR

Ferone D, et al. Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1. J Clin Endocrinol Metab. Published October 8, 2024. 

https://edge.prnewswire.com/c/link/?t=0&l=en&o=4733797-1&h=762902397&u=https%3A%2F%2Fdoi.org%2F10.1210%2Fclinem%2Fdgae707&a=https%3A%2F%2Fdoi.org%2F10.1210%2Fclinem%2Fdgae707

Camurus’ resubmitted NDA for CAM2029, a once-monthly subcutaneous octreotide depot for acromegaly, has been accepted by FDA with a PDUFA target action date of December 18, 2026. The prior complete response letter centered on cGMP inspection observations at a third-party manufacturer, not clinical efficacy or safety, and remediation has reportedly been completed. The application is supported by ACROINNOVA phase 3 data and additional clinical studies. CAM2029 is already authorized in the EU/UK as Oczyesa and is designed for self-administration.

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Hormonal Disorders

FDA Accepts Resubmitted CAM2029 NDA for Acromegaly

Although inhibition of the renin-angiotensin system with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), followed by sodium-glucose cotransporter 2 (SGLT2) inhibitors, has transformed

management by slowing disease progression, growing attention has shifted toward additional biological pathways that contribute to ongoing kidney and cardiovascular injury.

Among these, aldosterone has emerged as an increasingly important therapeutic target through the development of steroidal and nonsteroidal mineralocorticoid receptor antagonists, as well as newer aldosterone synthase inhibitors designed to reduce hormone production upstream.

, Marc Richards, MD, a nephrologist at Florida Kidney Physicians, discusses how advances in CKD pathophysiology have reshaped treatment over the past several decades, why aldosterone has become a key focus for clinicians, and what its physiologic role means for patients with kidney and cardiovascular disease.

Q&A: Why Aldosterone Has Become a Key Target in CKD Care, With Marc Richards, MD

Over the last couple of years and decades, our understanding of CKD pathophysiology has evolved considerably. Which biological pathways do you think have most changed the way clinicians approach treatment?

Richards: I think the big ones are really with ACE inhibitors, ARBs, and SGLT2 inhibitors; it's really all about tubuloglomerular feedback, reducing stress on the kidney.

And then also now we have a focus on targeting aldosterone as a way of trying to help limit stress on the kidney or limit stress on the heart, with older drugs like spironolactone and eplerenone, newer medicines like finerenone, and even looking into novel agents like aldosterone synthase inhibitors, which recently hit the market, to even prevent the aldosterone from being released in the first place.

Could you give a brief overview of aldosterone—what it does physiologically and why clinicians should pay attention to it?

Richards: Aldosterone is a hormone that's released by the adrenal gland, typically in response to either just being released on its own in cases of primary hyperaldosteronism, or in the setting of excess renin release, which can also increase that release because renin can stimulate that.

We know that aldosterone can lead to hypertension. It can lead to hypokalemia. It can lead to stress in patients with secondary release in patients with heart or liver dysfunction, and it probably has issues in the setting of—can possibly lead to—worsening renal dysfunction as well over time.

Fioretti F, Testani JM, Tio MC, Pitt B, et al. Aldosterone and aldosterone modulation in cardio-kidney diseases. 

. 2025;86(5):354-373. doi:10.1016/j.jacc.2025.06.012.

Chronic kidney disease therapeutics have historically centered on renin-angiotensin system blockade with ACE inhibitors and ARBs, later complemented by SGLT2 inhibitors to restore tubuloglomerular feedback and reduce intraglomerular stress. Attention is increasingly shifting toward aldosterone as an additional driver of ongoing renal and cardiovascular injury. Mineralocorticoid receptor antagonism now spans legacy steroidal agents, newer nonsteroidal options such as finerenone, and emerging aldosterone synthase inhibitors aimed at suppressing hormone production upstream, with implications for hypertension, hypokalemia, and progressive organ dysfunction.

Michael Richards, MD, discusses aldosterone's role in CKD pathophysiology and why targeting this pathway may reshape kidney disease treatment.

Why Aldosterone Has Become a Key Target in CKD Care, With Marc Richards, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

The FDA granted traditional approval to Novartis’ iptacopan (Fabhalta) for adults with primary IgA nephropathy, supported by phase 3 APPLAUSE-IgAN data showing slowed kidney function decline and sustained proteinuria reductions.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

FDA Grants Full Approval to Iptacopan (Fabhalta) in IgAN

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

New secondary endpoint analyses from Phase 3 LATITUDE PsO 3001 and 3002 reveal high rates of clearance on high-impact areas.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Zasocitinib: High Rates of Clearance for Scalp, Nail, Palmoplantar PsO

Boadie Dunlop, MSC, professor and chair of psychiatry and health behavior at the Medical College of Georgia at Augusta University.

Boadie Dunlop, MD, discusses COMP360 dosing-day monitoring, treatment resistance, and where psilocybin may fit among existing TRD options.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

COMP360 Psilocybin for TRD: What to Know Before a Possible 2027 Launch 

A recent analysis of data from the Global Burden of Disease Study has indicated a relationship between risk of death from ACHD and socioeconomic factors.

Structural Heart Disease

ACHD Mortality Displays Correlation With Lower Household Income, Lack of Insurance

Thanai Pongdee, MD, discusses 4-year PIONEER data showing avapritinib's quality of life, symptom, and safety benefits in indolent systemic mastocytosis remain durable.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Avapritinib 4-Year Data Show Durable Quality of Life Gains in ISM

Allan B. Massie, PhD, is an associate professor in the Department of Surgery and an associate professor in the Department of Population Health at NYU Langone.

NYU Langone’s Conor Donnelly, Allan Massie, and Michal Mankowski explain why follow-up after kidney transplant referral is critical to improving access.

Don’t Forget to Follow Up After Kidney Transplant Referral

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

A multidisciplinary clinical forum discussed diagnosis, referral thresholds, and the evolving APOC3-targeted treatment landscape for FCS.

Diagnosing and Treating Familial Chylomicronemia Syndrome: Perspectives from a Clinical Forum

Dr. Martin is an assistant professor at the Ciccarone Center for the Prevention of Heart Disease at the Johns Hopkins University School of Medicine.

Seth Martin, MD, MHS, discusses his recent study, which produced an AI-optimized equation that only requires 1 line of code.

New Martin-Hopkins LDL-C-Estimating Equation Simplifies Implementation for Comparable Results

New data support advancement of the Phase 3 PALM-PAH trial, a randomized, double-blind, placebo-controlled study now enrolling, with change in 6MWD as its primary endpoint.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Daily Inhaled TPIP Improved PAH Measures at 12 Months in OLE

Rajiv Agarwal, MD, MS, is a Professor Emeritus of Medicine at Indiana University School of Medicine and VA Medical Centre in Indianaoplis.

Phase 3 FIND-CKD data show finerenone slows kidney decline and reduces CV events in adults with nondiabetic CKD, Rajiv Agarwal, MD, adds his perspective. 


Type 2 Diabetes

Type 1 Diabetes

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Latest News

Expanding Era of Evidence-Based CKD Care, With Marc Richards, MD

Oral GP-SOD for Vitiligo: Safety Profile, Dosing, and What's Next

Enlicitide Receives FDA Approval for Hypercholesterolemia Following CORALreef Trials

FDA Accepts Resubmitted CAM2029 NDA for Acromegaly

Why Aldosterone Has Become a Key Target in CKD Care, With Marc Richards, MD